Opinions
David Driscoll
Ipsen SA
IPSEY-OTC
TOP PICK
Feb 15, 2019
Targetting oncology mostly. Small cap. Growing at a rapid rate. Debt to EBITDA is only 2x. Spending 13% of revenues on R&D, which is pretty hefty. (Analysts’ price target is $143.07)
$35.100
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising